Perspectives in the Field of Drug Metabolism

References

• Samanin R., Mennini T., Ferraris A., Bendotti C., Borsini F., Garattini S. M-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats, Naunyn Schmiedebergs Arch. Pharmacol. 1979; 308: 159–163
   Google Scholar
• Garattini S., Mennini T., Samanin R. From fenfluramine race-mate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake. Ann. NY Acad. Set. 1987; 499: 156–166
   PubMed Web of Science ®Google Scholar
• Samanin R., Mennini T., Bendotti C., Barone D., Caccia S., Garattini S. Evidence that central 5-HT2 receptors do not play an important role in the anorectic activity of d-fenfluramine in the rat. Neuropharmacolog. 1989; 28: 465
   PubMed Web of Science ®Google Scholar
• Invernizzi R., Fracasso C., Caccia S., Di A., Clemente Garattini S., Samanin R. Effect of L-cysteine on the long-term depletion of brain indoles caused by p-chloroamphetamine and d-fenfluramine in rats. Relation to brain drug concentrations. Eur. J. Pharmacol. 1989; 163: 77
   PubMed Web of Science ®Google Scholar
• Murray M., Zaluzny L. Comparative effects of antithrombotic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases. in vitro, Biochem. Pharmacol. 1988; 37: 415
   PubMed Web of Science ®Google Scholar
• Alvarez J., Montero M., Garcia-Sancho J. Cytochrome P450 may regulate plasma membrane Ca2+ permeability according to the filling state of the intracellular Ca2+ stores. FASEB J. 1992; 6: 786
   PubMed Web of Science ®Google Scholar
• Villalobos C., Fonteriz R., Lopez M. G., Garcia A. G., Garcia-Sancho J. Inhibition of voltage-gated Ca2 entry into GH 3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers. FASEB J. 1992; 6: 2742
   PubMed Web of Science ®Google Scholar
• Garattini S., Bizzi A., Caccia S., Mennini T. Progress report on the anorectic effects of fenfluramine, fluoxetine and sertraline. Int. J. Obes., in press
   Web of Science ®Google Scholar
• Gobbi M., Frittoli E., Mennini T., Garattini S. Comparative effects of antithrombotic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases in vitro. Biochem. Pharmacol. 1988; 37: 415–420
   PubMed Web of Science ®Google Scholar
• Garattini S., Mennini T., Samanin R. Central serotonergic mechanisms and feeding regulation. Neurochemical Pharmacology: A Tribute to B. B. Brodie, E. Costa. Raven Press, New York 1989; 89
   Google Scholar
• Mennini T., Borroni E., Samanin R., Garattini S. ldquo;Evidence of the existence of two different intraneuronal pools from which pharmacological agents can release serotonin”. Neurochem. Int. 1981; 3: 289–294
   PubMedGoogle Scholar
• Caccia S., Bizzi A., Coltro G., Fracasso C., Frittoli E., Mennini T., Garattini S. Anorectic activity of fluoxetine and norfluoxetine in rats: Relationship between brain concentrations and in vitro potencies on monoaminergic mechanisms. J. Pharm. Pharmacol. 1992; 44: 250
   PubMed Web of Science ®Google Scholar
• Goudie A. J., Thornton E. W., Wheeler T. J. Effects of Lilly 110140, a specific inhibitor of 5-hydroxytryptamine uptake, on food intake and on 5-hydroxytryptophan-induced anorexia: Evidence for serotoninergic inhibition of feeding. J. Pharm. Pharmacol. 1976; 28: 318
   PubMed Web of Science ®Google Scholar
• Wong D. T., Fuller R. W. Serotonergic mechanism in feeding. Int. J. Obes. 1987; 11(Suppl. 3)125
   PubMedGoogle Scholar
• Anelli M., Bizzi A., Caccia S., Codegoni A. M., Fracasso C., Garattini S. Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea-pigs. J. Pharm. Pharmacol. 1992; 44: 696
   PubMed Web of Science ®Google Scholar
• Mennini T., Bizzi A., Caccia S., Codegoni A. M., Fracasso C., Frittoli E., Guiso G., Martin I., Padura Taddei C., Uslenghi A., Garattini S. Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs. Naunyn Schmiedebergs Arch. Pharmacol 1991; 343: 483
   PubMed Web of Science ®Google Scholar
• Caccia S., Fracasso C., Garattini S., Guiso G., Sarati S. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacolog 1992; 31: 343
   PubMed Web of Science ®Google Scholar
• Garattini S., Bizzi A., Caccia S., Mennini T., Samanin R. Progress in assessing the role of serotonin in the control of food intake. Clin. Neuropharmacol. 1988; 11: S8, Suppl. 1
   PubMed Web of Science ®Google Scholar
• Amsterdam J., Brunswick D., Mendels J. ldquo;The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels”. Am. J. Psychiatr. 1980; 137: 653–662
   PubMed Web of Science ®Google Scholar
• Rudorfer M. V., Potter W. Z. Pharmacokinetics of antidepressants Psychopharmacology The Third Generation of Progress, H. Y. Meltzer. Raven Press, New York 1987; 1353
   Google Scholar
• Caccia S., Garattini S. ldquo;I-Arylpiperazines as active metabolites of (4-substituted aryl-1-piperazinyl) alkyl heterocyclic drugs”. Acta Pharmacol. Jugoslavi. 1990; 40: 441–460
   Google Scholar
• Jue S. G., Dawson G. W., Brogden R. N. ldquo;Amoxapine: A review of its pharmacology and efficacy in depressed states”. Drug. 1982; 24: 1–23
   PubMed Web of Science ®Google Scholar
• Rudorfer M. V., Potter W. Z. Antidepressants: A comparative review of the clinical pharmacology and therapeutic use of the “newer” versus the “older” drugs. Drug. 1989; 37: 713–738
   PubMed Web of Science ®Google Scholar
• Cohen B. M., Harris P. Q., Altesman R. I., Cole J. O. Amoxapine: Neuroleptic as well as antidepressant?. Am. J. Psychiatr. 1982; 139: 1165
   PubMed Web of Science ®Google Scholar
• Hollister L. E. ldquo;Current antidepressants”. Annu. Rev. Pharmacol. Toxicol. 1986; 26: 23–37
   PubMed Web of Science ®Google Scholar
• Caccia S. vivo metabolism of 4-substituted arylpiperazines to pharmacologically active I-arylpiperazines. Boll. Chim. Farm. 1990; 129: 183
   PubMedGoogle Scholar
• Gammans R. E., Mayol R. F., Labudde J. A. Metabolism and disposition of buspirone. Am. J. Med. 1986; 80(Suppl. 3B)41
   PubMed Web of Science ®Google Scholar
• Mennini T., Caccia S., Garattini S. ldquo;Mechanism of action of anxiolytic drugs”. Progr. Drug Res. 1987; 31: 315–347
   PubMedGoogle Scholar
• Bianchi G., Caccia S., Delia F., Vedova Garattini S. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite, 1-(2-pyrimidinyl)-piperazine (PmP). Eur. J. Pharmacol. 1988; 151: 365
   PubMed Web of Science ®Google Scholar
• Cervo L., Grignaschi G., Samanin R. ldquo;Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: Involvement of a metabolite”. Life Sci. 1988; 43: 2095–2102
   PubMed Web of Science ®Google Scholar
• Singer B. N-Nitroso alkylating agents: Formation and persistence of alkyl derivatives in mammalian nucleic acids as contributing factors in carcinogenesis, J. Natl. Cancer Inst. 1979; 62: 1329–1339
   Google Scholar
• Bonfanti M., Magagnotti C., Galli A., Bagnati R., Moret M., Gariboldi P., Fanelli R., Airoldi L. Determination of O6-butylguanine in DNA by immunoaffinity extraction/gas chromatogra-phy-mass spectrometry. Cancer Res. 1990; 50: 6870–6875
   PubMed Web of Science ®Google Scholar
• Airoldi L., Galli A., Magagnotti C., Bagnati R., Lolli M., Fanelli R. Urinary excretion of O-butylguanine after the administration of N-nitroso-N-butylurea in rats. Cancer Res. 1992; 52: 6699–6701
   PubMed Web of Science ®Google Scholar
• Bertini R., Coccia R, Pagani P., Marinello C., Salmona M., D'lncalci M. Interferon inducers increase 6-alkylguanine-DNA alkyl-transferase in the rat liver. Carcinogenesi. 1990; 11: 181–183
   PubMed Web of Science ®Google Scholar
• Coccia P., Bertini R., Pagani P., Marinello C., Taverna P., Villa P., D'lncalci M. Comparative effects of antithrombotic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases in vitro. Biochem. Pharmacol. 1988; 37: 415–420
   PubMed Web of Science ®Google Scholar
• Mattes W. B., Hartley J. A., Kohn K. W. DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res. 1986; 14: 2971–2987
   PubMed Web of Science ®Google Scholar
• Kohn K. W., Hartley J. A., Mattes W. B. Comparative effects of antithrombotic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases in vitro. Biochem. Pharmacol. 1988; 37: 415–420
   PubMed Web of Science ®Google Scholar
• Hurley L. H., Warpehoski M. A., Lee C. S., Govren Mc J. P., Scahill T. A., Kelly R. C., Mitchell M. A., Wicnienski N. A., Gebhard I. ldquo;Sequence specificity of DNA alkylation by the unnatural enan-tiomer of CC-1065 and its synthetic analogs”. J. Am. Chem. So. 1990; 112: 4633–4649
   Web of Science ®Google Scholar
• Broggini M., Erba E., Ponti M., Ballinari D., Geroni C., Spreafico F., D'lncalci M. ldquo;Selective DNA interaction of the novel dis-tamycin derivative FCE 24517”. Cancer Res. 1991; 51: 199–204
   PubMed Web of Science ®Google Scholar
• Perera F., Mayer J., Santella R. M., Brenner D., Jeffrey A., Latriano L., Smith S., Warburton D., Young T. L., Tsai W. Y., Hemminki K., Brandt-Rauf P. Biologic markers in risk assessment for environmental carcinogens. Environ. Health Perspect. 1991; 90: 247–254
   PubMed Web of Science ®Google Scholar
• Mustonen R., Hietanenälä P., Lepp S., Takala M., Hemminki K. Determination of cis-diamminedichloroplatinum(II) in plasma proteins and hemoglobin of cancer patients. Arch. Toxicol. 1989; 63: 361
   PubMed Web of Science ®Google Scholar
• Perera F., Fischman H. K., Hemminki K., Brandt-Rauf P., Ni-man H. L., Smith S., Toporoff E., O'Dowd K., Tang M. X., Tsai W. Y., Stoopler M. Protein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy. Arch. Toxicol. 1990; 64: 401
   PubMed Web of Science ®Google Scholar
• Reed E., Yuspa S. H., Zwelling L. A., Ozols R. F., Poirier M. C. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest. 1986; 77: 545
   PubMed Web of Science ®Google Scholar
• Fichtinger-Schepman A. M. J., Van Oosterom A. T., Loh-man P. H. M., Berends F. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay?. Mutat. Res. 1987; 190: 59
   PubMed Web of Science ®Google Scholar
• Niman H. L., Thompson A. M., Yu A., Markman M., Willems J. J., Herwig K. R., Habib N. A., Wood C. B., Houghten R. A., Lerner R. A. ldquo;Antipeptide antibodies detect oncogene-related proteins in urine”. Proc. Natl. Acad. Sci. 1985; 82: 7924–7928
   PubMed Web of Science ®Google Scholar
• Subramanyam B., Woolf T., Castagnoli N. Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem. Res. Toxicol. 1991; 4: 123–128
   PubMed Web of Science ®Google Scholar
• Subramanyam B., Rollema H., Woolf T., Castagnoli N. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 1990; 166: 238–244
   PubMed Web of Science ®Google Scholar
• Shields P. G., Harris C. C. ldquo;Molecular epidemiology and the genetics of environmental cancer”. J. Am. Med. Asso. 1991; 266: 681–687
   PubMed Web of Science ®Google Scholar
• Perera F. R. ldquo;Molecular cancer epidemiology: A new tool in cancer prevention”. J. Natl. Cancer Inst. 1987; 78: 887–898
   PubMed Web of Science ®Google Scholar
• Vineis P., Esteve J., Hartge P., Hoover R., Silverman D. T., Terracini B. ldquo;Effects of timing and type of tobacco in cigarette-induced bladder cancer”. Cancer Res. 1988; 48: 3849–3852
   PubMed Web of Science ®Google Scholar
• Bryant M. S., Vineis P., Skipper P. L., Tannenbaum S. R. ldquo;Hemo-globulin adducts of aromatic amines: Associations with smoking status and type of tobacco”. Proc. Natl. Acad. Sci. 1988; 85: 9788–9791
   PubMed Web of Science ®Google Scholar
• Malaveille C., Vineis P., Esteve J., Ohshima H., Brun G., Haute-feuille A., Gallet P., Ronco G., Terracini B., Bartsch H. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer. Carcinogenesi. 1989; 10: 577–586
   PubMed Web of Science ®Google Scholar
• Hattis D. Use of biological markers and pharmacokinetics in human health risk assessment. Environ. Health Perspecl. 1991; 90: 229–238
   PubMed Web of Science ®Google Scholar
• Skipper P. L., Tannenbaum S. R. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesi. 1990; 11: 507–518
   PubMed Web of Science ®Google Scholar
• Shamsuddin A. K. M., Sinopoli N. T., Hemminki K., Boesch R. R., Harris C. C. Detection of benzo(a)pyrene:DNA adducts in human white blood cells. Cancer Res. 1985; 45: 66–68
   PubMed Web of Science ®Google Scholar
• Mirkes P. E., Brown N. A., Kajbaf M., Lamb J. H., Farmer P. B., Naylor S. Identification of cyclophosphamide-DNA adducts in rat embryos exposed in vitro to 4-hydroperoxycyclophosphamide. Chem. Res. Toxicol. 1992; 5: 382
   PubMed Web of Science ®Google Scholar
• Everson R. B., Randerath E., Avitts T. A., Schut H. A., Randerath K. Preliminary investigations of tissue specificityspecies specificity, and strategies for identifying chemicals causing DNA adducts in human placenta. Progr. Exp. Tumor Res. 1987; 31: 86
   PubMed Web of Science ®Google Scholar
• Smith C. A. D., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maranganore D. M., Sturman S. G., Schapira A. H. V., Williams A. C., Spurr N., Wolf C. R. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lance. 1992; 339: 1375–1377
   PubMed Web of Science ®Google Scholar
• Ford J. M., Hait W. N. ldquo;Pharmacology of drugs that alter multidrug resistance in cancer”. Pharmacol. Rev. 1990; 42: 155–199
   PubMed Web of Science ®Google Scholar
• Endicott J. A., Ling V. The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989; 58: 137
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Bio-phys. Acta. 1976; 455: 152
   PubMed Web of Science ®Google Scholar
• Juranka P. F., Zastawny R. L., Ling V. p-Glycoprotein: Multidrug resistance and a superfamily of membrane-associated transport proteins, FASEB J. 1989; 3: 2583–2592
   Google Scholar
• Chambers T. C., Avoy Mc E. M., Jacobs J. W., Eilon G. Protein kinase C phosphorylates p-glycoprotein in multidrug resistant human KB carcinoma cells. J. Biol. Chem. 1990; 265: 7679
   PubMed Web of Science ®Google Scholar
• Broggini M., Grandi M., Ubezio P., Geroni C., Giuliani F. C., Dtncalci M. ldquo;Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline”. Biochem. Pharmacol. 1988; 37: 4423–4431
   PubMed Web of Science ®Google Scholar
• Ramu A., Pollard H. B., Rosario L. M. ldquo;Doxorubicin resistance in P388 leukemia–evidence for reduced drug influx”. Int. J. Cance. 1989; 44: 539–547
   PubMed Web of Science ®Google Scholar
• Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985; 45: 3002–3007
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981; 41: 1967
   PubMed Web of Science ®Google Scholar
• Dtncalci M., Broxterman H. J., Kalken C. K. Membrane transport in multidrug resistance, development, and disease. Ann. Oncol. 1991; 2: 635
   PubMed Web of Science ®Google Scholar
• Garattini S. Some experimental therapeutic approaches for osteosarcoma Frontiers in Osteosarcoma Research. Hogrefe & Huber, Berna, in press
   Google Scholar
• Tsuruo T, Iida H., Naganuma K., Tsukagoshi S., Sakurai Y. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res. 1983; 43: 808–813
   PubMed Web of Science ®Google Scholar
• ÉPierr A., Kraus-Berthier L., Atassi G., Cros S., M-Poupon F., Lavielle G., Berlion M., Bizzari J. P. Preclinical antitumor activity of a new vinca alkaloid derivative, S 12363. Cancer Res. 1991; 51: 2312
   PubMed Web of Science ®Google Scholar
• Sato W., Fukazawa N., Suzuki T, Yusa K., Tsuruo T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res. 1991; 51: 2420
   PubMed Web of Science ®Google Scholar
• Shinoda H., Inaba M., Tsuruo T. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52, Cancer Res. 1989; 49: 1722–1726
   Google Scholar
• Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833, Cancer Res. 1991; 51: 4226–4233
   Google Scholar
• Redmond S. M. S., Joncourt F., Buser K., Ziemiecki A., Alter-matt J., Fey M., Margison G., Cerny T. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and G6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res. 1991; 51: 2092–2097
   PubMed Web of Science ®Google Scholar
• Ganapathi R., Grabowsky D., Sweatman W., Seshadri R., Israel M. N-Benzyladriamycin-14-valerate versus progressively doxoru-bicin-resistant murine tumours: Cellular pharmacology and characterisation of cross-resistance. vitroand in vivo, Br. J. Cance 1989; 60: 819
   PubMed Web of Science ®Google Scholar
• Sweatman T. W., Israel M., Koseki Y., Seshadri Y., Beck W. T. Cytotoxicity and cellular pharmacology of N-benzyladriamycin-14-valerate in mechanistically different multidrug-resistant human leukemic cells. J. Cell. Pharmacol. 1990; 1: 95
   Google Scholar
• Lothstein L., Sweatman T. W., Dockter M. E., Israel M. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res. 1992; 52: 3409
   PubMed Web of Science ®Google Scholar
• Danks M. K., Yalowich J. C., Bech W. T. ldquo;Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (WM-26)”. Cancer Res. 1987; 47: 1297–1301
   PubMed Web of Science ®Google Scholar
• Nieuwint A. W., Baas F., Wiegant J., Joenje H. Cytogenetic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines. Cancer Res. 1992; 52: 4361–4371
   PubMed Web of Science ®Google Scholar
• Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988; 48: 1926
   PubMed Web of Science ®Google Scholar
• Sugawara I., Nakahama M., Hamada H., Tsuruo T., Mori S. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170,000–180,000 P-glycoprotein. Cancer Res. 1988; 48: 4611
   PubMed Web of Science ®Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. US. 1987; 84: 7735
   PubMed Web of Science ®Google Scholar
• Lieberman D. M., Reithmeier R. A., Ling V., Charuk J. J., Goldberg H., Skorecki K. L. Identification of P-glycoprotein in renal brush border membranes. Biochem. Biophys. Res. Commun. 1989; 162: 244
   PubMed Web of Science ®Google Scholar
• Kane S. E., Pastan I., Gottesman M. M. ldquo;Genetic basis of multidrug resistance of tumor cells”. J. Bioenerg. Biomembr. 1990; 22: 593–618
   PubMed Web of Science ®Google Scholar
• Ames B. N., Gold L. S. ldquo;Endogenous mutagens and the causes of aging and cancer”. Mutat. Res. 1991; 250: 3–16
   PubMed Web of Science ®Google Scholar
• Cordon C., Cardo J. P., O'Brien Casals D., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. US. 1989; 86: 695
   PubMed Web of Science ®Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Comparative effects of antithrombotic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases in vitro. Biochem. Pharmacol. 1988; 37: 415–420
   PubMed Web of Science ®Google Scholar
• Vander P., Valk C. K., Ketelaars H., et al. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann. Oncol. 1990; 1: 56
   PubMed Web of Science ®Google Scholar
• Speeg K. V., deLeon C., Guire Mc W. L. ldquo;Uptake of the non-cytotoxic transport probe procainamide in the Chinese hamster ovary model of multidrug resistance”. Cancer Res. 1992; 52: 3539–3546
   PubMed Web of Science ®Google Scholar
• Mickisch G. H., Pastan I., Gottesman M. M. ldquo;Multidrug resistant transgenic mice as a novel pharmacologic tool”. Bioessay. 1991; 13: 381–387
   PubMed Web of Science ®Google Scholar
• Pastan I., Willingham M. C., Gottesman M. ldquo;Molecular manipulations of the multidrug transporter: A new role for transgenic mice”. FASEB J. 1991; 5: 2523–2528
   PubMed Web of Science ®Google Scholar
• Galski H., Sullivan M., Willingham M. C., et al. ldquo;Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance of daunomycin-induced leukopenia”. Mol. Cell. Biol. 1989; 9: 4357–4363
   PubMed Web of Science ®Google Scholar
• Tsuruo T. ldquo;Mechanisms of multidrug resistance and implications for therapy”. Jpn. J. Cancer Res. 1988; 79: 285–296
   PubMedGoogle Scholar
• Mickisch G. H., Pai L. H., Gottesman M. M., Pastan I. ldquo;Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice”. Cancer Res. 1992; 52: 4427–4432
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Smit J. J. M., Wagenaar E., et al. Efficient inac-tivation of the mouse mdr genes in embryonic stem cells using homologous recombination. Proc. Am. Assoc. Cancer Res. 1992; 33: 466
   Google Scholar
• Glisson B., Gupta R., Smallwood-Kentro S., Ross W. ldquo;Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: Loss of drug-stimulated DNA cleavage activity”. Cancer Res. 1986; 46: 1934–1938
   PubMed Web of Science ®Google Scholar
• Pommier Y., Kerrigan D., Schwartz R. E., Swack J. A., Mc-Curdy A. ldquo;Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors”. Cancer Res. 1986; 46: 3075–3081
   PubMed Web of Science ®Google Scholar
• Hamilton T. C., Winker M. A., Louie K. G., et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sul-foximine mediated glutathione depletion. Biochem. Pharmacol. 1985; 34: 2583
   PubMed Web of Science ®Google Scholar
• Wang A. L., Tew K. D. ldquo;Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards”. Cancer Treat. Rep. 1985; 69: 677–682
   PubMedGoogle Scholar
• Alaoui M. A., Panasci L., Centurioni G. M., Schecter R., Lehnert S., Batist G. ldquo;Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity”. Cancer Chemother. Pharmacol. 1992; 30: 341–347
   PubMed Web of Science ®Google Scholar
• Tagliabue G., Pifferi A., Balconi G., Geroni C., D'lncalci M., Ubezio P. ldquo;Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting antineoplastic agents”. Int. J. Cance. 1993; 54: 435–442
   PubMed Web of Science ®Google Scholar
• Kelley S. L., Basu A., Teicher B. A., Hacker M. P., Hamer D. H., Lazo J. S. ldquo;Overexpression of metallothionein confers resistance to anticancer drugs”. Scienc. 1988; 241: 1813–1815
   PubMed Web of Science ®Google Scholar
• Tagliabue G., Citti L., Massazza G., Damia G., Giavazzi R., D'lncalci M. Tumor levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts. Anticancer Res. 1993, in press
   Web of Science ®Google Scholar
• Ames B. N., Profet M., Gold L. S. ldquo;Dietary pesticides (99.99% all natural)”. Proc. Natl. Acad. Sci. US. 1990; 87: 7777–7781
   PubMed Web of Science ®Google Scholar
• Pantuck E. J., Hsiao K. C., Loub W. D., Wattenberg L. W., Kuntzman R., Conney A. H. ldquo;Stimulatory effect of vegetables on intestinal drug metabolism in the rat”. J. Pharmacol. Exp. Ther. 1976; 198: 278–283
   PubMed Web of Science ®Google Scholar
• Wattenberg L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 1992; 52: 2085s
   PubMed Web of Science ®Google Scholar
• Danell Mc R., Lean Mc A. E. M., Hanley A. B., Heaney R. K., Fenwick G. R. ldquo;Chemical and biological properties of indole glucos-inolates (glucobrassicins): A review”. Food Chem. Toxicol. 1988; 26: 59–70
   PubMed Web of Science ®Google Scholar
• Goeger D. E., Shelton D. W., Hendricks J. D., Bailey G. S. Mechanisms of anticarcinogenesis by indole-3-carbinol: Effect on the distribution and metabolism of aflatoxin B 1 in rainbow trout. Carcinogenesi. 1986; 7: 2025–2031
   PubMed Web of Science ®Google Scholar
• Wattenberg L. W., Loub W. D. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res. 1978; 38: 1410–1412
   PubMed Web of Science ®Google Scholar
• Shertzer H. G. ldquo;Protection by indole-3-carbinol against covalent binding of benzo[a]pyrene metabolites to mouse liver DNA and protein”. Food Chem. Toxicol. 1983; 21: 31–35
   PubMed Web of Science ®Google Scholar
• Shertzer H. G. Indole-3-carbinol protects against covalent binding of benzo[a]pyrene and N-nitrosodimethylamine metabolites to mouse liver macromolecules. Chem.-Biol. Interact. 1984; 48: 81–90
   PubMed Web of Science ®Google Scholar
• Wattenberg L. W. Inhibition of neoplasia by minor dietary constituents. Cancer Res 1983; 43: 2448s
   PubMed Web of Science ®Google Scholar
• Bradfield C. A., Bjeldanes L. F. ldquo;Structure-activity relationships of dietary indoles: A proposed mechanism of action as modifiers of xenobiotic metabolism”. J. Toxicol. Environ. Healt. 1987; 21: 311–323
   PubMed Web of Science ®Google Scholar
• Wattenberg L. W. Studies of polycyclic hydrocarbon hydroxylases of the intestine possibly related to cancer. Effect of diet on benzopyrene hydroxylase activity. Cance. 1971; 28: 99–102
   PubMed Web of Science ®Google Scholar
• Dashwood R. H., Arbogast D. N., Fong A. T., Hendricks J. D., Bailey G. S. Mechanisms of anticarcinogenesis by indole-3-carbinol: Detailed in vivo DNA binding dose-response studies after dietary administration with aflatoxin B 1. Carcinogenesi. 1988; 9: 427
   PubMed Web of Science ®Google Scholar
• Dashwood R. H., Arbogast D. N., Fong A. T., Pereira C., Hendricks J. D., Bailey G. S. Quantitative interrelationships between aflatoxin B, carcinogen dose, indole-3-carbinol anticarcinogen dose, target organ DNA adduction and final tumor response. Carcinogenesi. 1989; 10: 175
   PubMed Web of Science ®Google Scholar
• Sparnins V. L., Chuan J., Wattenberg L. W. Enhancement of glutathione S-transferase activity of the esophagus by phenols, lactones, and benzyl isothiocyanate. Cancer Res. 1982; 42: 1205
   PubMed Web of Science ®Google Scholar
• Benson A. M., Barretto P. B. Effects of disulfiram, dieth-yldithiocarbamate, bisethylxanthogen, and benzyl isothiocyanate on glutathione transferase activities in mouse organs. Cancer Res. 1985; 45: 4219
   PubMed Web of Science ®Google Scholar
• Leonard T. B., Popp J. A., Graichen M. E., Dent J. G. ldquo;Betanaphthylisothiocyanate-induced alterations in hepatic drug metabolism and liver morphology”. Toxicol. Appl. Pharmacol. 1981; 60: 527–534
   PubMed Web of Science ®Google Scholar
• Zhang Y., Talalay P., Cho C. G., Posner G. H. ldquo;A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure”. Proc. Natl. Acad. Sci. US. 1992; 89: 2399–2403
   PubMed Web of Science ®Google Scholar
• Bailey G. S., Hendricks J. D., Shelton D. W., Nixon J. E., Pawlowski N. E. ldquo;Enhancement of carcinogenesis by the natural anticarcinogen indole-3-carbinol”. J. Natl. Cancer Inst. 1987; 78: 931–934
   PubMed Web of Science ®Google Scholar
• R Dashwood H., Fong A. T., Williams D. E., Hendricks J. D., Bailey G. S. Promotion of aflatoxin B, carcinogenesis by the natural tumor modulator indole-3-carbinol: Influence of dose, duration, and intermittent exposure on indole-3-carbinol promotional potency. Cancer Res. 1991; 51: 2362
   PubMed Web of Science ®Google Scholar
• Birt D. F., Pelling J. C., Pour P. M., Tibbels M. G., Schweickert L., Bresnick E. ldquo;Enhanced pancreatic and skin tumorigenesis in cabbage-fed hamsters and mice”. Carcinogenesi. 1987; 8: 913–917
   PubMed Web of Science ®Google Scholar
• Wattenberg L. W. ldquo;Chemopre vent ion of cancer”. Cancer Res. 1985; 45: 1–8
   PubMed Web of Science ®Google Scholar
• Elson C. E., Maltzman T. H., Boston J. L., Tanner M. A., Gould M. N. Anticarcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesi. 1988; 9: 331–332
   PubMed Web of Science ®Google Scholar
• Karlson B., Leijd B., öm Hellstr K. ldquo;On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment”. Acta Med. Scand. 1986; 220: 347–350
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., et al. ldquo;A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2”. Surger. 1986; 100: 262–272
   PubMed Web of Science ®Google Scholar
• Colombo N., Peccatori F., Paganin C., et al. Antitumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int. J. Cance 1992; 51: 42
   PubMed Web of Science ®Google Scholar
• Gorodischer R, Krasner J., Mc J. J., Nolan J. P., Yaffe S. J. ldquo;Hepatic microsomal drug metabolism after administration of endotoxin in rats”. Biochem. Pharmacol. 1976; 25: 351–353
   PubMedGoogle Scholar
• Chang K. C., Bell T. D., Lauer B. A., Chai H. ldquo;Altered theophylline pharmacokinetics during acute respiratory viral illness”. Lance. 1978; 1: 1132–1133
   PubMed Web of Science ®Google Scholar
• Bertini R., Ghezzi P. Depression of liver drug metabolism in sarcoma-bearing mice. Evidence for a circulating factor and dissociation from lipolytic activity. Eur. J. Cance. 1988; 24: 1845
   Web of Science ®Google Scholar
• Garattini S., Ghezzi P., D'lncalci M. ldquo;Effects of cancer disease on the metabolism of anticancer agents”. Pharmacol. Ther. 1988; 37: 57–65
   PubMed Web of Science ®Google Scholar
• Bartosek I., Donelli M. G., Guaitani A., Colombo T., Russo R., Garattini S. ldquo;Differences of cyclophosphamide and 6-mercaptopurine metabolic rates in perfused liver of normal and tumor-bearing animals”. Biochem. Pharmacol. 1975; 24: 289–291
   PubMed Web of Science ®Google Scholar
• Kramer P., Clain Mc C. J. ldquo;Depression of aminopyrine metabolism by influenza vaccination”. N. Engl. J. Med. 1981; 305: 1262–1268
   PubMed Web of Science ®Google Scholar
• Gooderham N. J., Mannering G. J. ldquo;Depression of cytochrome P-450 and alterations of protein metabolism in mice treated with the interferon inducer polyriboinosinic acid-polyribocytidylic acid”. Arch. Biochem. Biophys. 1986; 250: 418–425
   PubMed Web of Science ®Google Scholar
• Ghezzi P., Saccardo B., Villa P., Rossi V., Bianchi M., Dinarello C. A. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect. Immun. 1986; 54: 837–840
   PubMed Web of Science ®Google Scholar
• Ghezzi P., Saccardo B., Bianchi M. ldquo;Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice”. Biochem. Biophys. Res. Commun. 1986; 136: 316–321
   PubMed Web of Science ®Google Scholar
• Dinarello C. A., Cannon J. G., Wolff S. M., et al. ldquo;Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1”. J. Exp. Med. 1986; 163: 1433–1450
   PubMed Web of Science ®Google Scholar
• Chen Y. L., Florentin I., Batt A. M., Ferrari L., Giroud J. P., Chauvelot-Moachon L. ldquo;Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat”. Biochem. Pharmacol. 1992; 44: 137–148
   PubMed Web of Science ®Google Scholar
• Bertini R., Bianchi M., Villa P., Ghezzi P. ldquo;Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin 1 and tumor necrosis factor: A comparison with lymphotoxin and interferon”. Int. J. Immunopharmacol. 1988; 10: 525–530
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. ldquo;Interleukin-1 and the pathogenesis of the acute-phase response”. N. Engl. J. Med. 1984; 311: 1413–1418
   PubMed Web of Science ®Google Scholar
• The Acute Phase Response to Injury and Infection, A. H. Gordon, A. Koj. Elsevier, Amsterdam 1985
   Google Scholar
• Bertini R., Bianchi M., Erroi A., Villa P., Ghezzi P. Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron. J. Leukoc. Biol. 1989; 46: 254
   PubMed Web of Science ®Google Scholar
• Ghezzi P., Saccardo B., Bianchi M. ldquo;Induction of xanthine oxidase and heme oxygenase and depression of liver drug metabolism by interferon: A study with different recombinant interferons”. J. Interferon Res. 1986; 6: 251–256
   PubMedGoogle Scholar
• Cantoni L., Rossi C., Rizzardini M., Gadina M., Ghezzi R. ldquo;Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids”. Biochem. J. 1991; 279: 891–894
   PubMed Web of Science ®Google Scholar
• Deloria L., Abbott V., Gooderham N., Mannering G. J. ldquo;Induction of xanthine oxidase and depression of cytochrome P-450 by interferon inducers: Genetic difference in the responses of mice”. Biochem. Biophys. Res. Commun. 1985; 131: 109–114
   PubMed Web of Science ®Google Scholar
• Duan L., Ghezzi P., Conti I., Tridico R. V., Bianchi M., Caccia S. Recombinant tumor necrosis factor reduces hepatic drug metabolism in vivo in the rat. J. Biol. Response Mod. 1988; 7: 365–370
   PubMedGoogle Scholar
• Murray M., Reidy G. F. ldquo;Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents”. Pharmacol. Rev. 1990; 42: 85–101
   PubMed Web of Science ®Google Scholar
• Barrett A. J. Introduction: The classification of proteinases. Protein Degradation in Health and Disease, D. Evered, J. Whelan. Excerpta Medica, Amsterdam 1980; 1
   Google Scholar
• Tanaka H., Kaneko T. Pharmacokinetic and pharmacodynamic comparisons between human granulocyte colony-stimulating factor purified from human bladder carcinoma cell line 5637 culture medium and recombinant human granulocyte colony-stimulating factor produced. Escherichia coli, J. Pharmacol. Exp. Ther. 1992; 262: 439
   PubMed Web of Science ®Google Scholar
• Tanaka H., Kaneko T. ldquo;Sex differences in the pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat”. Drug Metab. Dispos. 1991; 19: 1034–1039
   PubMed Web of Science ®Google Scholar
• Tanaka H., Tokiwa T. ldquo;Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat”. Cancer Res. 1990; 50: 6615–6619
   PubMed Web of Science ®Google Scholar
• Tanaka H., Satake-Ishikawa R., Ishikawa M., Matsuki S., Asano K. Comparative effects of antithrombotic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases in vitro. Biochem. Pharmacol. 1988; 37: 415–420
   PubMed Web of Science ®Google Scholar
• Tanaka H., Okada Y., Kawagishi M., Tokiwa T. ldquo;Pharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the rat”. J. Pharmacol. Exp. Ther. 1989; 251: 1199–1203
   PubMed Web of Science ®Google Scholar
• Roques B. P., Beaumont A. Neutral endopeptidase-24.11 inhibitors: From analgesics to antihypertensives'?. Trends Pharmacol. Sci. 1990; 11: 245
   PubMed Web of Science ®Google Scholar
• J-Schwartz C., Gros C., J-Lecomte M., Bralet J. Enkephalinase (EC 3.4.24.11.) inhibitors: Protection of endogenous ANF against in-activation and potential therapeutic applications. Life Sci. 1990; 47: 1279–1297
   PubMed Web of Science ®Google Scholar
• Roques B. P., Fournie-Zaluski M. C., Soroca E., et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Natur. 1980; 288: 286
   PubMed Web of Science ®Google Scholar
• O'Connell J., E., Jardine A. G., Davidson G., Connell J. M. C. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J. Hypertens. 1992; 10: 271
   PubMed Web of Science ®Google Scholar
• Schwartz J. C., Malfroy B., De S., Baume La. Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxy-peptidase (“enkephalinase”) as neuropeptidase. Life Sci 1981; 29: 1715
   PubMed Web of Science ®Google Scholar
• Samanin R., Mennini T, Bendotti C., Barone D., Caccia S., Garattini S. Evidence that central 5HT 2 receptors do not play an important role in the anorectic activity of D-fenfluramine in the rat. Neuropharmacolog. 1989; 28: 465
   PubMed Web of Science ®Google Scholar
• Rama N. V. S., Devanesan P. D., Rogan E. G., et al. Mechanism of metabolic activation of the potent carcinogen 7,12-dimethylbenz[a]anthracene. Chem. Res. Toxicol. 1992; 5: 220
   PubMed Web of Science ®Google Scholar
• Sabbioni G. Chemical and physical properties of the major serum albumin adduct of aflatoxin B 1 and their implications for the quantification in biological samples. Chem.-Biol. Interact. 1990; 75: 1
   PubMed Web of Science ®Google Scholar
• Walker V. E., Neela Mac J. P., Swenberg J. A., Turner M. J., Fennell T. R. Molecular dosimetry of ethylene oxide: Formation and persistence of N-(2-hydroxyethyl)valine in hemoglobin following repeated exposures of rats and mice. Cancer Res. 1992; 52: 4320
   PubMed Web of Science ®Google Scholar
• Walker V. E., T Fennell R., Upton P. B., et al. Molecular dosimetry of ethylene oxide: Formation and persistence of 7-(2-hydroxyethyl)guanine in DNA following repeated exposures of rats and mice. Cancer Res. 1992; 52: 4328–4334
   PubMed Web of Science ®Google Scholar